platform integrates research, clinical development, and manufacturing capabilities to support the delivery of advanced cancer therapies. The company concentrates on making these therapies more accessible and cost-efficient, particularly in markets where such treatments are limited or expensive. It develops end-to-end capabilities that include cell processing, vector manufacturing, and clinical-grade production systems for immunotherapy products. This infrastructure supports both ongoing clinical trials and future commercialization of CAR-T therapies for blood cancers such as lymphomas and leukemias.